ACN Newswire

Hong Kong Tech Innovators Drive Success at Mobile World Congress and 4YFN Barcelona 2026

HONG KONG, March 6, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), led a delegation of 20 local innovation and technology (I&T) companies and institutions to Barcelona, Spain, concluding a highly successful participation at the world’s premier connectivity event—Mobile World Congress (MWC), and debuted at the startup-centric stage—4 Years From Now (4YFN) 2026. This participation has enabled local tech firms to access markets overseas, showcasing their strengths in research and development (R&D), and demonstrating the city’s role as a leading international I&T hub.The delegation effectively spotlighted Hong Kong’s cutting-edge innovative solutions in Connectivity, Devices and Systems, Digital Transformation, and support from Ecosystem Partners, successfully engaged global industry leaders and investors to generate business collaboration, technology co-development and investment opportunities.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “Hong Kong is committed to developing into an international I&T centre, actively promoting cross-industry integration and driving high-quality development of the industries through technological innovation. We possess a robust mobile communications infrastructure, and the industry is highly competitive in research and development as well as technology related to 5G/6G applications and AI integration. This year, the Hong Kong Tech Pavilion adopts a dual-pavilion layout to showcase the city's I&T capabilities on two international platforms – MWC and 4YFN – helping the industry expand into European and broader global business opportunities.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC and 4YFN bring together the world’s most influential stakeholders across connectivity and innovation ecosystems. Our dual-zone presence gave our innovators the global stage to validate solutions, gain visibility and drive business traction. HKSTP will continue to strengthen the I&T ecosystem and bring Hong Kong's research excellence to Europe and beyond.”A series of dialogues and exchanges—spanning networking reception and themed talks to pitching sessions—were held at the Pavilions and attracted an enthusiastic response. The events highlighted the dynamism of Hong Kong’s I&T ecosystem to European audiences, while enabling participants to more deeply understand the city’s unique advantages as a “super-connector” and “super value-adder”. This positions the city as a strategic springboard for international companies entering Asian markets, while enabling local and Chinese Mainland firms to leverage this edge to expand globally.Following his visit to the Hong Kong Tech Pavilion, Alejandro Gallego, International Business Director of AMEC, said: “The Hong Kong Pavilions are highly inspirational, and the exhibiting companies we visited showcased exceptionally innovative technological solutions. We have started conversations with Hong Kong companies to explore concrete opportunities for collaboration.”Jacobo Pérez-Soba, Manager of the Internationalisation Department, Madrid Chamber of Commerce & Industry, said: “The solutions and services provided by Hong Kong companies are highly forward-looking and demonstrate outstanding technological advancement. I also learned about upcoming tech events in Hong Kong, which are expected to be of significant interest to Spanish companies and startups.”As 2026 marks the opening year of China’s 15th Five-Year Plan, with technological innovation as one of the national priorities, HKTDC shall continue to join hands with HKSTP to support local tech firms in "going global" through jointly organising the Hong Kong Tech Pavilion, accelerating Hong Kong’s I&T by building a vibrant, internationally competitive ecosystem and fostering the development of new quality productive forces.Photo download: https://bit.ly/3Nm5qHlHong Kong Tech Pavilion debuted a dual presence at MWC and 4YFN 2026, featuring 20 Hong Kong I&T companies and institutions in Barcelona to showcase the city’s innovative technology solutions. Throughout the four-day event, the Hong Kong Tech Pavilion at MWC saw a constant stream of visitors, attracting a significant number of international telecom operators, corporate decision-makers, and investors. The Hong Kong Tech Pavilion debuted at the startup-centric 4YFN, served as a vibrant stage for Hong Kong’s up-and-coming innovation power. A series of dialogues and exchanges—spanning networking reception and themed talks to pitching sessions—were held at the MWC Pavilion and attracted an enthusiastic response. The seminar “Ready for Asia' Take the Fast Track Through Hong Kong” was held at the Pavilion to share strategies for international companies to enter Asian markets, speakers included (starts from the second left in Photo 6) Chris Lo, Regional Director, Europe, Central Asia & Israel of HKTDC; Paula Kant, Head, Investment Promotion of InvestHK; Jennifer Chan, Board Member of HKSTP; Prof Christopher Chao, Senior Vice President (Research and Innovation) of The Hong Kong Polytechnic University and Daniel Garcia, Founder of a Spain startup VirtuaBroker. Another seminar, the "Hong Kong Tech Disrupt" featured insights from Jennifer Chan, Board Member of HKSTP (first from left); Derek Chim, Head of Startup Ecosystem and Development of HKSTP (middle); alongside were representatives from park companies, including Kinson Chan, CEO of eSIX Limited (second from right) and Edward Mak, CEO & Founder of Vista InnoTech (second from left). The seminar drew attention from numerous professionals in the European technology sector.Full list of 20 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026:MWC 2026 – Booth 6E44 at Hall 61Entoptica LimitedDevices & Systems2eSIXConnectivity3Faraconix Technologies Co., Ltd.Connectivity4FreightAmigo Services LimitedDigital Transformation5Glassdio Scientific Company LimitedConnectivity6Harvest Elite International LimitedDigital Transformation7HongKong Umedia LimitedDevices & Systems8iASPEC Services LimitedDigital Transformation9InvestHKEcosystem Partners10Robocore Technology LimitedDevices & Systems11Shannon & Turing Technology LimitedConnectivity12The Hong Kong Polytechnic UniversityEcosystem Partners13Xeroptix TechnologyDevices & Systems4YFN 2026 – Booth 8.1B31 at Hall 8.114AIGM LimitedDigital Transformation15BWSea Technology (HK) Co., LimitedDigital Transformation16Cresento LimitedDevices & Systems17GoGoChart Technology LimitedDigital Transformation18HairCoSys LimitedDevices & Systems19KNQ Technology LimitedDigital Transformation20Vista Innotech LimitedDevices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and over 2,400 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at www.hkstp.org.Media Contact:Hong Kong Science and Technology Parks CorporationAngela Lau, +852 6535 7611, angela.lau@hkstp.orgHong Kong Trade Development CouncilWinnie Kan, +852 2584 4055, winnie.wy.kan@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Business

蝙蝠侠2可能刚刚找到了它的新反派

Warner Bros. Pictures(SeaPRwire) -   随着超级英雄疲劳的争论年复一年地展开，2022年的《蝙蝠侠》完全避开了这场讨论，这简直是个奇迹。在《莫比亚斯》和《黑亚当》等备受瞩目但遭遇评论和商业失败的影片出现的时期，《蝙蝠侠》却是一股清流，一部霓虹闪烁的黑色电影，深受粉丝和评论家喜爱，并获得了超过7.7亿美元的票房。导演马特·里夫斯对黑暗骑士的描绘，与（其他蝙蝠侠系列）不同，让粉丝们着迷，以至于四年后，他们仍在痛苦地等待着备受期待的续集的更新。现在，时机终于到了，《蝙蝠侠2》已经进入了前期制作，零星的消息也逐渐浮出水面。已经确认的是，除了原片中的大部分演员回归外，还有两位漫威的旧将加盟，塞巴斯蒂安·斯坦将饰演哈维·丹特，斯嘉丽·约翰逊将饰演一个未公开的角色（可能饰演他的妻子吉尔达）。现在有传言称另一位一线明星可能加盟，尽管尚未证实，但这些传言指向了一个在蝙蝠侠最伟大的反派之一的诞生过程中扮演部分角色的角色的到来。《蝙蝠侠》是DC多年来最大的成功。| Warner Bros. PicturesGiantFreakinRobot 报道称，丹尼尔·克雷格据称已获得在《蝙蝠侠2》中饰演克里斯托弗·丹特的角色。哈维·丹特，即双面人的父亲，克里斯托弗是一个有趣的角色，他在漫画中的戏份并不多，但他曾在其他蝙蝠侠的媒体中出现过，最著名的是作为哈维在《蝙蝠侠：阿卡姆》系列游戏中的背景故事的一部分。在漫画和他其他的出场中，克里斯托弗都被描绘成一个有虐待倾向的酒鬼（有时他自己也与分离性身份识别障碍作斗争），他会抛掷一枚只有一面的硬币，假装是否要殴打儿子是随机的。如果传言属实，里夫斯可能会给我们带来一个独特的双面人形象，这与汤米·李·琼斯的滑稽表演或克里斯蒂安·贝尔在《黑暗骑士》中突然的复仇式转变大相径庭。深入挖掘哈维的虐待史可能会让他更接近《蝙蝠侠：动画系列》中的双面人；虽然那个版本中的“大坏蛋哈维”的形成是校园恶霸造成的，但将其替换为与他父亲的暴力关系很容易达到相同的目的。我们可能不会看到一个在突如其来的悲剧压力下崩溃的哈维·丹特，而是看到一个在压抑了几十年的童年创伤和爆炸性愤怒后崩溃的丹特。《蝙蝠侠：动画系列》中的双面人源于童年创伤。| DC Studios在《蝙蝠侠》中，马特·里夫斯深入挖掘了布鲁斯·韦恩的心理，将他描绘成一个寻求通过私刑来发泄的、情感发育迟缓的男人。在《蝙蝠侠2》中，里夫斯可以为这个角色最复杂的反派之一带来同样的深度，将双面人的诞生变成一场歌剧式、充满情感的事件。关于克雷格是否会加盟的传闻是否属实还有待观察，但可以肯定的是，哈维·丹特的引入意味着当续集最终到来时，蝙蝠侠与犯罪的斗争将变得更加混乱。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

SeaPRwire

CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Latest News

随着富人撤离中东，私人航班占阿曼机场出港航班的30%

(SeaPRwire) -   随着“史诗狂怒行动”不断升级，漫长的边境通关、SUV车队以及价值六位数的包机，已成为人们逃离中东的新途径。目前，私人航班占从[此处原文缺失地点]出发航班总数的近三分之一。实时航班跟踪平台FlightRadar24报告称，尽管阿曼仍然是疏散和遣返航班的“重要”枢纽，但周三在马斯喀特国际机场，私人航班占运营航班总数的31%。截至周四下午，该平台报告称，机场所有起降航班中，超过30%为私人航班。本周早些时候，Semafor报道称，[此处原文缺失地点]的机场吸引了想要离开这些国家的超级富豪旅客。知情人士告诉该媒体，私人安保公司一直在预订[此处原文缺失内容]，载着人们从迪拜驱车10小时前往沙特阿拉伯的利雅得，在那里可以搭乘私人航班。据Semafor报道，撤离该地区的客户包括全球金融公司的高级管理人员，以及来该地区出差或度假的富有的旅行者。LIV高尔夫球手[此处原文缺失姓名]，这位两次大满贯赛冠军，只是在这场混乱中安排航班撤离的富豪之一。拉赫姆通过与私人航空公司VistaJet的合作安排了一架包机，在七名被困的LIV高尔夫球手及其球童的航班取消后，将他们从阿曼送往[此处原文缺失地点]。经过四个多小时的车程抵达阿曼后，一行人飞往了香港。全球私人飞机和货运代理公司Air Charter Service的一位发言人告诉福克斯商业频道，该公司已经安排了10多次撤离航班，还有更多航班已列入计划，主要是从阿曼起飞，搭载想要逃离迪拜的乘客。这位发言人表示：“我们撤离了一些来该地区出差的员工，我们安排他们通过哈塔边境口岸从阿联酋进入阿曼，将他们送到马斯喀特，然后从那里飞离该地区。截至周日，通过哈塔边境口岸的通关时间约为3 - 4小时，但我猜现在这个时间可能更长了，因为有更多人选择这条路线。”据[此处原文缺失媒体名称]报道，从阿曼马斯喀特飞往[此处原文缺失地点]的轻型喷气式飞机航班费用超过9.3万美元，该媒体称这个价格约为平时的两倍。该媒体还补充说，重型喷气式飞机在同一路线上的费用最高可达14万美元。美国和以色列于周六发起了[此处原文缺失行动名称]，引发了针对该地区有美国利益存在的国家的报复性袭击。美国领事事务助理国务卿莫拉·南达尔建议美国公民离开巴林、埃及、伊朗、伊拉克、以色列、约旦河西岸和加沙地带、约旦、科威特、黎巴嫩、阿曼、卡塔尔、沙特阿拉伯、叙利亚、阿拉伯联合酋长国和也门。由于公民和旅行者纷纷试图逃离，可用飞机数量有限，导致[此处原文缺失情况]。Digital的瑞安·莫里克和阿什利·卡纳汉对本报道亦有贡献。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

ACN Newswire

Anime Tokyo Station: “That Time I Got Reincarnated as a Slime” Special Exhibition, February 21 to May 24, 2026

TOKYO, Mar 6, 2026 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station is an anime exhibition site focused on Japanese anime content, which has developed a devout fan base around the world. From February 21 (Sat.) to May 24 (Sun.), 2026, it will be holding the “That Time I Got Reincarnated as a Slime” Special Exhibition. A preview was held for the press on February 20 (Fri.), the day before the exhibition opened.©Taiki Kawakami, Fuse, KODANSHA/ “Ten-Sura” ProjectThis special exhibition looks back on the story through the third season of the TV anime, highlighting iconic scenes and memorable lines. Visitors can enjoy exhibits unique to Anime Tokyo Station, including interactive digital content and a photo spot where they can take commemorative photos with Rimuru. With displays that unfold alongside character introductions and other features, even those who have not yet seen the anime can enjoy the exhibition as preparation for the film set for release in late February and the fourth season of the TV anime starting in April.Come to Anime Tokyo Station and experience the appeal of “That Time I Got Reincarnated as a Slime.”Exhibits©Taiki Kawakami, Fuse, KODANSHA/ “Ten-Sura” ProjectAbout the SeriesWhat is “That Time I Got Reincarnated as a Slime”?“That Time I Got Reincarnated as a Slime” is an isekai anime series following a protagonist who is reincarnated as a slime in another world, using the skills he acquires along with his wits and courage to gather allies. The first season of the TV anime aired on TOKYO MX and other channels from October 2018 to March 2019.In 2021, TV anime Season 2 Part 1 aired from January to March, followed by the spin-off comic adaptation “Slime Diaries: That Time I Got Reincarnated as a Slime” from April to June, and TV anime Season 2 Part 2 from July to September, making for nine consecutive months of broadcasts. Then, on November 25, 2022, “That Time I Got Reincarnated as a Slime: The Movie – Scarlet Bond” was released nationwide, becoming a major hit with over one million admissions and box office revenue of 1.4 billion yen in Japan.To commemorate the 10th anniversary of the web novel “That Time I Got Reincarnated as a Slime,” the Tensura 10th Project launched on February 20, 2023. As part of this project, the all-new three-episode animation “That Time I Got Reincarnated as a Slime: Visions of Coleus” began streaming on November 1, 2023. On December 16, 2023, the series’ first large-scale event, That Time I Got Reincarnated as a Slime: Tensura 10th Live, was held at Mori no Hall 21 in Matsudo. Furthermore, the third season of the TV anime aired from April to September 2024. Following the final episode of Season 3, production of a second theatrical film and Season 4 of the TV anime was announced. “That Time I Got Reincarnated as a Slime: The Movie – Tears of the Azure Sea” is set to release on February 27, 2026.The original manga “That Time I Got Reincarnated as a Slime” (serialized in Kodansha’s Monthly Shonen Sirius / Manga: Taiki Kawakami, Original story: Fuse, Character design: Mitz Vah) is a comic adaptation of the popular web novel of the same name by Fuse, which surpassed 1 billion page views on the user-generated novel publishing website “Shosetsuka ni Naro.” The combined worldwide circulation of the manga, novels, and spin-off works has exceeded 56 million copies (as of June 2025).* “Shosetsuka ni Naro” is a registered trademark of HinaProject Inc.Tensura Portal Site: ten-sura.comOfficial X: @ten_sura_anime / Official Instagram: tensura_official / Official TikTok: @ten_sura_animeEvent OverviewTitle:“That Time I Got Reincarnated as a Slime” Special ExhibitionDates:February 21, 2026 to May 24, 2026Name:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo) * 4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m. / Special exhibitions close: 6:30 p.m.)Closed:Mondays* If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/SNS:X｜https://x.com/animetokyo_info　（@animetokyo_info）Instagram｜https://www.instagram.com/animetokyostation/（@animetokyostation）YouTube｜https://www.youtube.com/channel/UCSJOjGJE5Yiqw3PZ97AVdJwInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: https://www.acnnewswire.com/docs/files/20260306.pdf  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Business

十年后，一个星际迷航时代或将戛然而止

派拉蒙+(SeaPRwire) -   即使是那些只是略微关注好莱坞内部消息的人，也可以肯定地说，目前派拉蒙正在发生很多变化。而且，拥有《星际迷航》系列版权的母公司几乎肯定正在朝着某种方向转变。这种转变是否激进还有待观察，但有一点是肯定的：自[此处信息缺失]以来，《星际迷航》第二季结束后，首次没有新的《星际迷航》电视剧正在制作中。至少没有公开宣布的新剧。[此处信息缺失]指出，《星际舰队学院》第二季拍摄的结束，让我们来到了现代《星际迷航》制作历史上一个奇怪的时刻。《发现号》于2016年宣布，10年前，也就是2016年开始制作。《发现号》最终于2017年在CBS全接入平台（现为派拉蒙+）播出，从那时起，至少有一部，通常是多部不同的《星际迷航》系列剧正在制作中。就在三年前，即2023年，粉丝们还在为[此处信息缺失]的成功、[此处信息缺失]的精彩以及《下层甲板》第四季而欢呼。2024年和2025年，该系列开始缩减，[此处信息缺失]和[此处信息缺失]的结局都在那一年播出，还有[此处信息缺失]，这似乎也预示着该系列的结束。保罗·吉亚玛提和霍利·亨特出席《星际舰队学院》首映礼。| 斯蒂芬妮·奥杰洛/THR/《好莱坞报道者》/盖蒂图片社这或多或少把我们带到了当下：《奇异新世界》第三季——在因编剧罢工而推迟后——于2025年发布，由[此处信息缺失]主演的独立流媒体电影《第31区》也是如此。有那么一瞬间，《奇异新世界》是唯一正在播出的新《星际迷航》电视剧，但今年早些时候《星际舰队学院》第一季的发布改变了这一情况。因为这部剧刚刚结束第二季的拍摄，在2026年3月12日第一季大结局播出后，我们至少还能再看到10集。《奇异新世界》第四季预计今年晚些时候播出，很有可能在秋季发布，以庆祝9月8日的《星际迷航》60周年纪念日。之后，在2027年，精简后的最后一季，共6集的第五季将结束《奇异新世界》，截至撰写本文时，该剧也已完成拍摄。长期的《星际迷航》老将乔纳森·弗雷克斯也注意到了这一停顿或不确定时期，他在最近的一次采访中向《逆时》证实，他没有执导《星际舰队学院》第二季或《奇异新世界》第五季的任何一集。当被问及是否有他执导的《星际迷航》剧集正在制作中但我们尚未看到（在《第300夜》发布之后）时，弗雷克斯直接表示：“据我所知没有。”这意味着，截至目前，《星际舰队学院》第9集是弗雷克斯执导的最新的《星际迷航》故事。乔纳森·弗雷克斯执导《星际舰队学院》。| 派拉蒙+这会是他的最后一部吗？或者更关键的是：2028年会成为自2017年以来第一部没有新的《星际迷航》系列剧的年份吗？目前有一部《星际迷航》故事片正处于早期阶段，由《龙与地下城》的导演执导，看起来这个正在开发的项目可能会在《星际舰队学院》的另一季或全新的《星际迷航》系列剧之前推出。但话又说回来，这一切可能都没什么意义，《星际舰队学院》很可能会有第三季，并且在2027年之后可能会有一系列新的《星际迷航》剧集。就此而言，现任《星际迷航》负责人在接受《逆时》采访时表示，他认为《星际舰队学院》有一个“无限的故事讲述引擎”，该系列可以持续很长时间。《星际迷航》系列此前也曾经历过激进的变革时刻。从1987年到2005年，该系列连续播出了18年的电视剧，之后似乎结束了，但四年后又以由J·J·艾布拉姆斯执导的大片电影系列的形式重新出现。唱反调的人都预测由《发现号》开启的流媒体《星际迷航》时代不会长久，但它至少持续了过去十年，甚至可能更久。2027年之后，新一代的《星际迷航》会是什么样子呢？唯一知道答案的人要么是时间旅行者，要么是Q连续体的成员。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。《星际舰队学院》第一季在派拉蒙+上播出。